Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | EBP | Q15125 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446590 | 1.00 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL13995262 | 1.00 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL13519646 | 1.00 | SIGMAR1 (0.53) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL16943589 | 0.87 | SIGMAR1 (0.60) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL21566192 | 0.87 | SIGMAR1 (0.60) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL13223790 | 0.85 | SIGMAR1 (0.63) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL104617 | 0.85 | SIGMAR1 (0.63) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL11122622 | 0.84 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL9361316 | 0.84 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4EATMALDH1A1 | |
| SCHEMBL10812144 | 0.84 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4EATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | SIGMAR1 663/4885EBP 549/4885KDM4E 3170/4885 |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | SIGMAR1 663/4885EBP 549/4885KDM4E 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.